2024
DOI: 10.1080/14737167.2024.2379600
|View full text |Cite
|
Sign up to set email alerts
|

Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial

Heng Xiang,
Kehui Meng,
Meiyu Wu
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 43 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?